Short answer
Compass Therapeutics, Inc. (CMPX) filed an 8-K current report with the SEC on March 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q4/full-year 2025 earnings disclosure filed March 5, 2026: full results in referenced exhibit, not detailed in this item text.
Compass Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q4/full-year 2025 earnings disclosure filed March 5, 2026: full results in referenced exhibit, not detailed in this item text
- Neil Lerner, Chief Accounting Officer, signed filing: no CFO signature, notable for a small-cap biotech
- Investors should review Exhibit 101 (Inline XBRL) for actual financial figures
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Compass Therapeutics, Inc. 8-K filings
Get the next CMPX 8-K as it lands
Follow CMPX for push alerts, or ask the research agent what this filing means.